KROS

Keros Therapeutics, Inc. Common Stock
Data: 2026-08-03

Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.

Quick Stats
Aug 03, 2026

48.0

AI Score

HOLD

0.27

Volume Ratio

Aug 05, 2026

Next Earnings

12

+ve Days (30d)

18

-ve Days (30d)

KROS Stock Summary

Last updated Aug 03, 2026

KROS is currently trading at $10.06, positioned below its 200-day moving average of $14.21, suggesting bearish momentum. The stock has a 52-week range of $9.69 to $22.55.

Technical Analysis: The 50-day moving average stands at $10.69, which is above the current price, indicating bearish near-term pressure. The RSI (Relative Strength Index) reads 39.657, suggesting the stock is neutral with balanced momentum.

Money Flow Indicators: The Chaikin Money Flow (20-day) is 0.064, which is positive, indicating accumulation by institutional investors. Our AI-powered investment score rates KROS at 48.0/100 with a HOLD recommendation.

KROS (Keros Therapeutics, Inc. Common Stock) Indicators

Last updated Aug 03, 2026

Indicator Value
RSI(14) 39.657
CMF (20) 0.064
ROC (10) -6.503
ADX (14) 17.041
Indicator Value
MACD (12,26,9) -0.249
AROONOSC (14) -92.857
WILLAMS %R (14) -92.245
MFI (14) 31.406
KROS Technical Chart
  • Candlesticks: Green = price up, Red = price down. Body shows open/close, wicks show high/low.
  • SMAs: Moving averages help identify trends. Price above SMA = bullish, below = bearish.
  • Options OI: Shows max open interest strikes. High OI = significant price levels.
  • Volume Profile: Shows price levels with most trading activity. POC = Point of Control (highest volume).
  • Earnings: Vertical lines mark earnings dates. Watch for volatility around these dates.
  • Gamma Walls: Key support/resistance from options gamma exposure. Orange = resistance above, Purple = support below.
  • Fibonacci Retracement: Auto-calculated support/resistance levels based on recent high/low. Key levels: 23.6%, 38.2%, 50%, 61.8%, 78.6%.
  • Unusual Activity: Highlights days with abnormal volume (2x+ average) or large price moves (5%+). Red marker = unusual activity detected.
Technical Indicators

Select indicators above to analyze technical patterns

Indicators will appear below the price chart with perfectly aligned dates

Volume Profile Analysis

Horizontal histogram showing volume distribution at each price level with buying/selling pressure

KROS Price vs Max Options Open Interest
KROS Max Change In Options Open Interest

KROS Options - Sort by Max open Interest (near term)

3rd August 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike OI Change in
OI
Volume Ask PC Delta Vega Volatility % change Track

KROS Daily Out of Money Options - Sort by Max open Interest (near term)

3rd August 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike OI Change in
OI
Volume Ask PC Delta Vega Volatility % change Track

KROS Daily In the Money Options - Sort by Max open Interest (near term)

3rd August 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike OI Change in
OI
Volume Ask PC Delta Vega Volatility % change Track

KROS Most Active Options by Volume(near term)

3rd August 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike Volume OI Change in
OI
Ask PC Delta Vega Volatility % change Track

Keros Therapeutics, Inc. Common Stock is below both the 50 Day and 200 Day SMA which is considered Bearish.

KROS Moving Averages Analysis

KROS (Keros Therapeutics, Inc. Common Stock) Simple Moving Averages

Moving Averages are last updated Aug 03, 2026

Days MA
10 10.16
20 10.66
30 10.75
50 10.69
100 11.03
200 14.21

KROS Fundamental Analysis

P/E (Forward) 48.7805
P/E (Trailing) --
Market Cap ($) 202.3 million
Earnings/Share ($) -2.59
Net Profit Margin (%) -2.566
Dividend/Share ($) --
EPS Estimate Current Year ($) -5.186
EPS Estimate Next Year ($) -5.5933
WallStreet Target Price ($) 21.83
Most Recent Quarter